Company Limery-Pharma Srl with Fiscal Code 33785015
recorded a turnover of 2024 of
30.155,
with a net profit of
9.193
and having an average number of employees of
- .
The company operates in the field of Comerţ cu amănuntul al produselor farmaceutice having the NACE code 4773.
Sales - Ron
Sales, Profit, Employees, Total Income, Financial Results -
Limery-Pharma Srl
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Sales - EUR
58.993
20.285
26.597
26.234
25.490
25.222
24.460
26.818
28.505
30.155
Total Income - EUR
62.274
20.285
26.597
26.234
25.490
25.222
24.460
26.818
28.505
31.230
Total Expenses - EUR
59.168
12.524
18.134
17.805
28.767
14.679
39.150
17.771
16.150
20.285
Gross Profit/Loss - EUR
3.106
7.761
8.463
8.429
-3.277
10.542
-14.689
9.047
12.355
10.945
Net Profit/Loss - EUR
1.801
7.152
7.666
7.642
-4.042
9.984
-15.423
8.242
10.378
9.193
Employees
1
0
0
0
0
0
0
0
0
0
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity as found at the Ministry of Finance. The data provides the evolution of the company during this period regarding the increases and possibly decreases recorded.
In the last year of activity, the sales increased by 6.4%, from 28.505 euro in the year 2023, to 30.155 euro in 2024.
The Net Profit decreased by -1.127 euro, from 10.378 euro in 2023, to 9.193 in the last year.
Check the financial reports for the company - Limery-Pharma Srl
Financial Rating - LIMERY-PHARMA SRL
See the company's note based on the submitted financial data, relative to the industry of which it is a part.
Financial Rating
Payment Limits - Limery-Pharma Srl
See the company's payment capacity for situations in which you conclude contracts with payment terms.
Check Payment Limits
Prob. of insolvency - Limery-Pharma Srl
It determines the risk of insolvency based on the submitted accounting balance.
Insolvency Probability
Financial Reports - Limery-Pharma Srl
Check all the financial reports of the company and know the risks in collaboration with it.
Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of
21.174 euro in 2024 which includes Inventories of
0 euro, Receivables of
12.072 euro and cash availability of
9.102 euro.
The company's Equity was valued at
34.024 euro, while total Liabilities amounted to
169 euro.
Equity increased by 9.193 euro, from 24.970 euro in 2023, to 34.024 in 2024.
Similar services useful for checking companies and business development.
SellNet
Get the contact details for any company and get in touch with it.
Sectoral Studies
Knows the market and develops its own development strategies according to sectorial data.
Databases
Export in excel files the data of the companies selected according to the desired criteria.
Import - Export
Find importers and exporters according to the type of activity and the countries in which they carry it out.
Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.
Comments - Limery-Pharma Srl